Targeting SPINK5-mediated immune suppression to restore anti-tumor immunity could improve the effectiveness of immune checkpoint therapies, including anti-PD-1/PD-L1 and anti-CTLA-4 treatments (Table 3). This evidence concerns the gene CTLA4 and neoplasm.